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Letters to the Editorvalidity, and perhaps the relevance of
such hemodynamic measurements.
In regard to the effects on diastolic
function induced by SVR, he ignores
our article published in Circulation
in 2004,3 in which we demonstrated
that SVR induces a mechanical re-
synchronization through improve-
ment of contraction and relaxation
phases leading to early improvement
in diastolic function, despite the
marked reduction of end-diastolic vol-
ume. These data have been confirmed
at follow-up in a more recent article.4
Diastolic filling depends on several
‘‘static and dynamic’’ variables, and
in our opinion it is too simplistic to
infer that surgical reduction of end-
diastolic volume equates with induc-
tion of impaired diastolic function.
End-diastolic volume reduction during
SVR is the consequence of scar tissue
exclusion. Moreover, an increase in
stiffness does not necessarily mean
a reduction of ventricular filling and
worsening of clinical status, given
that many dynamic factors can par-
tially compensate for alterations in
elastic properties of the ventricular
wall. On the other hand, a majority of
healthy elderly individuals are free of
disease despite the presence of left
ventricular diastolic dysfunction as de-
tected by echocardiography. In addi-
tion, it is well known that diastolic
dysfunction is neither necessary nor
sufficient for thedevelopmentofaheart
failure clinical syndrome: Additional
complex interactions with metabolic,
neurohormonal, and especially renal
factors are likely to be required.5 At
present, we do not think that valid
data exist to show that SVR induces
changes in diastolic function that are
able to turn heart failure with reduced
ejection fraction into heart failure
with preserved ejection fraction!
With specific regard to our article,
Dr Buckberg seems to assume ‘‘a pri-
ori’’ that a reduction in SV necessarily
implies aworsening of hemodynamics
and, parenthetically, cardiovascular
equilibrium. In our article, and more
precisely in our previous response toThe JournalParachuri, we emphasized that post-
SVR SV reduction was not present in
all patients but only in those with rest-
ing SV higher than normal, whereas in
patients with reduced resting SV, SVR
induces an increase in SV. We hypoth-
esized that the resting SV higher than
normal and proportional to end-
diastolic volume increase was due to
‘‘congestion’’ in a vision of backward
heart failure mechanism, whereas the
increase in SV in patients with resting
decreased SV was likely due to ven-
tricular afterload reduction after
SVR. The message of our article was
that SVR, on the basis of our data,
tends to normalize resting SV, and
this is not at all in disagreement with
postoperative clinical improvement.
We think that one should not inter-
pret hemodynamic changes in a biased
way, taking into account mainly or
only the direction of changes, but
should frame them in a correct patho-
physiologic picture considering the
setting in which changes begin, the
meaning, and the mechanism underly-
ing such changes.
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We thank Dr Buckberg for his
thoughtful comments on our article.1
We obviously agree that a positive
correlation (or a ‘‘logical’’ relation-
ship) between clinical findings (in
our case New York Heart Association
class, quality-of-life score, and 6-min-
ute walking distance) and hemody-
namic measurements is reassuring
and supportive for the validity and
consistency of the entire data set.
The implicit and plausible assumption
is that patients would be expected to
profit from surgical ventricular resto-
ration (SVR) if this intervention
somehow improves their cardiovascu-
lar function. However, cardiovascular
function has many components, and
the relative importance of each com-
ponent on overall cardiovascular sta-
tus might depend on factors such as
the level of exertion.
Clinical parameters provide a highly
valuable overall outcome measure, but
a positive clinical response to SVR
does not necessarily imply that all com-
ponents of the underlying cardiovascu-
lar function have improved. With
regard to SVR, theoretical models pre-
dict that the intervention is a ‘‘balancing
act’’ betweenpositive effects on systolic
function and negative effects on dia-
stolic function.2 Our findings support
this hypothesis, but we also conclude
that based on more global parameters,
such as cardiac output and stroke
work, and the mentioned clinical pa-
rameters, the positive effects (improved
systolic function, reduced wall stress,
and reduced dyssynchrony) apparently
outweighed the negative effects (re-
duced diastolic function) in our patient
group. We believe that this type of
detailed analysis of cardiovascularry c Volume 142, Number 1 237
Letters to the Editorfunction is key to understanding the
working mechanisms of SVR
and explain the somewhat variable re-
ported success.3,4 The pathophysiology
of the selected patients, the details
of the surgical intervention, such as the
amount of volume reduction, the applied
additional surgical interventions, and the
interactions between these factors, all
could ‘‘tip the balance.’’ Identification
and quantification of the specific effects
of SVR on the various components of
cardiovascular function ultimately
might help to select optimal candidates
and potentially to further optimize
this intervention to put more weight on
the positive side and lift the negative
side.
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XENOTRANSPLANTATION
TECHNOLOGY PROVIDES
MATERIALS FOR IMPROVED
BIOPROSTHETIC HEART
VALVES
To the Editor:
In their recent article published in
the Journal,McGregor and colleagues1238 The Journal of Thoracic and Cprovide further evidence that biopros-
thetic heart valves (BHVs) constructed
from wild-type (genetically unmodi-
fied) porcine or bovine sources are
less than optimal, as previously re-
ported and discussed by others.2-5
Because of the expression of
Gala1,3Gal (Gal), and possibly other
porcine or bovine antigens, they
are susceptible to inflammation,
calcification, and failure.
The model used by McGregor and
colleagues is not ideal. (1) The pig tis-
sue was implanted into the subcutane-
ous tissue of the recipient, and
therefore was not in direct contact
with blood (in which anti-pig anti-
bodies circulate). (2) The pig tissue
was coated with anti-Gal antibody be-
fore implantation, rather than being
continually exposed to anti-pig anti-
bodies (which are continually being
produced by a human recipient, which
is not the case when a Gal-positive an-
imal, eg, rat or rabbit, is used as the
recipient of the graft). (3) The pig graft
was exposed only to anti-Gal anti-
bodies and not to other human
anti-pig (anti–non-Gal) antibodies.
Nevertheless, despite these limita-
tions, the authors clearly demonstrate
the detrimental effect of using porcine
or bovine tissues that are susceptible to
human anti-Gal antibodies and make
a strong case that tissues from a1,3-
galactosyltransferase gene-knockout
(GT-KO) pigs, which do not express
Gal, should be the sources of BHVs,
as suggested previously.2-5
As the authors point out, GT-KO
mice and pigs, both of which make
anti-Gal antibodies (and therefore
mimic humans in this respect), are
now readily available for future exper-
imental studies. However, despite the
reservations the authors express, the
pig-to-nonhuman primate model
would clearly be the optimal model.
Indeed, studies have already clearly
shown that GT-KO porcine tissues
elicit a weaker inflammatory response
than wild-type (unmodified) pig tis-
sues when implanted into nonhuman
primates.6ardiovascular Surgery c July 2011However, why limit clinical trials to
the use of tissues from GT-KO pigs,
when GT-KO pigs that express one or
more complement-regulatory proteins
(eg, CD46, CD55) are also available?
The expression of a complement-
regulatory protein would almost cer-
tainly protect the tissues further from
immune injury, particularly because
there will also be a response to non-
Gal antigens. Furthermore, pigs are
also becoming available that express
human anti-inflammatory or antithrom-
botic transgenes (eg, CD39 or thrombo-
modulin), which are likely to provide
even greater protection. It can realisti-
cally be concluded that survival of
BHVs from suchgenetically engineered
pigs would be extended significantly.
The biggest hurdle to the use of ge-
netically engineered pigs as sources
of BHVs, despite compelling reasons
to do so, would seem to be related to
business economics. The cost of ge-
netically engineered pigs would be
considerably more than the minimal
cost of wild-type pigs. As pointed
out previously,5 if a BHV from a ge-
netically engineered pig functioned
in the patient for a significantly longer
period of time, this would clearly be
in the patient’s interests, but it is un-
likely to be to the economic advan-
tage of the company supplying the
BHV. The cost of the BHV would be
significantly greater, and the need
for replacement would be signifi-
cantly reduced.
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